OMEROS CORP Proceeds from Long-Term Debt Issued
OMEROS CORP (OMER) reported Proceeds from Long-Term Debt Issued of $0 for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2015-11-09
- OMEROS CORP proceeds from issuance of long-term debt for the quarter ending 2015-09-30 was $0.00.
- OMEROS CORP proceeds from issuance of long-term debt for the quarter ending 2015-06-30 was $0.00.
- OMEROS CORP proceeds from issuance of long-term debt for the quarter ending 2015-03-31 was $0.00, a 100.00% decline year-over-year.
- OMEROS CORP proceeds from issuance of long-term debt for the quarter ending 2014-09-30 was $0.00.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month |
|---|---|---|---|
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $0.00 derived: sum of 2 quarters · filed 2015-11-09 | $0.00 10-Q · filed 2015-11-09 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $0.00 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $0.00 10-Q · filed 2015-05-11 | ||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $0.00 derived: sum of 2 quarters · filed 2015-11-09 | $12.70M 10-Q · filed 2015-11-09 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $12.70M 10-Q · filed 2015-08-10 | |
| 2014-03-31 | $12.70M 10-Q · filed 2015-05-11 | ||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $0.00 derived: sum of 2 quarters · filed 2014-11-10 | $0.00 10-Q · filed 2014-11-10 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $0.00 10-Q · filed 2014-08-11 | |
| 2013-03-31 | $0.00 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |